Moreover, we show that the effect of SERPINB3 loss on radiation sensitivity in cervical tumor cells is similar if not greater than cisplatin, currently used as the standard of care to radiosensitize cervical cancer. Here, SERPINB3 is linked to cervical carcinoma.